Skip to main content
Lexeo Therapeutics, Inc. logo

Lexeo Therapeutics, Inc. — Investor Relations & Filings

Ticker · LXEO ISIN · US52886X1072 US Manufacturing
Open in API
Filings indexed 289 across all filing types
Latest filing 2024-04-22 Board/Management Inform…
Country US United States of America
Listing US LXEO

About Lexeo Therapeutics, Inc.

https://www.lexeotx.com/

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to developing gene therapies for genetically defined diseases. The company is advancing a diverse pipeline of investigational adeno-associated virus (AAV)-based gene therapy candidates. Its primary areas of focus are rare cardiovascular diseases and APOE4-associated Alzheimer's disease. Lexeo's strategy centers on addressing conditions with high unmet medical needs by leveraging pioneering science, including research originating from institutions such as Weill Cornell Medicine, to develop treatments with curative potential.

Recent filings

Filing Released Lang Actions
424B3
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 22, 2024, for Lexeo Therapeutics, Inc. It includes an announcement regarding a director (Bernard Davitian) not standing for re-election at the upcoming annual meeting. This is a clear announcement of a change in the company's board of directors. The document does not contain financial statements or detailed financial data, nor is it a report publication announcement or a proxy solicitation. Therefore, it fits the category of Board/Management Information (MANG). The document length (6421 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2024-04-22 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive license agreement with Cornell University, including detailed terms of the agreement. It also mentions a press release attached as an exhibit. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing to disclose a material event as required by the SEC. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (5889 characters) and content confirm it is a full filing, not just a report publication announcement.
2024-04-22 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 22, 2024, reporting a specific event: the departure of a director who is not standing for re-election. The key section is Item 5.02, which relates to changes in directors or officers. There is no financial data or report attached, nor is this an announcement of a report publication. The content clearly fits the category of Board/Management Information, as it announces a director's decision not to stand for re-election. The document length is short (3036 characters), consistent with a typical 8-K filing for management changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2024-04-22 English
424B3
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed by Lexeo Therapeutics, Inc. It includes a press release about the FDA granting Fast Track designation to a gene therapy candidate. The document is a regulatory filing reporting a material event but does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, earnings release, or any other detailed financial report. It is also not a proxy, capital update, or management change announcement. The document is a typical regulatory announcement of a significant event, fitting the Regulatory Filings (RNS) category.
2024-04-16 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an event where the FDA granted Fast Track designation to a gene therapy candidate, and it includes a press release as an exhibit. The document does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual/interim report. It is a regulatory announcement of a significant event. Given the nature and length (3080 characters), it is not a full report but a regulatory filing announcing an event. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-04-16 English
Regulatory Filings 2024
Regulatory Filings
2024-04-15 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.